Study outcomes
steatosis
LIVER FIBROSIS, STEATOSIS
The primary aim of this study is to compare the effect of 48 weeks of 20 mg daily atorvastatin versus placebo on CIMT in virally suppressed HIV patients with CMV seropositivity. Other aims are to assess:the interaction between baseline CMV copy number and the effect of atorvastatin on CIMT, FMD, neurocognitive function, liver fibrosis and steatosis, lipid profile, and immune activation biomarkers (sCD14, VCAM, ICAM, hsCRP, and β2M) changes in 48 weeks.the changes of lipid, liver fibrosis and steatosis, neurocognitive, several immune activation biomarkers, and CPI in virally suppressed HIV patients with CMV seropositivity given 48 weeks of 20 mg daily atorvastatin compared to placebo 